Genetic evidence for cytochrome b Qi site inhibition by 4(1H)-quinolone-3-diarylethers and antimycin in Toxoplasma gondii

P. Holland Alday, Igor Bruzual, Aaron Nilsen, Sovitj Pou, Rolf Winter, Choukri Ben Mamoun, Michael Riscoe, Joseph Doggett

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Toxoplasma gondii is an apicomplexan parasite that causes fatal and debilitating brain and eye disease. Endochinlike quinolones (ELQs) are preclinical compounds that are efficacious against apicomplexan-caused diseases, including toxoplasmosis, malaria, and babesiosis. Of the ELQs, ELQ-316 has demonstrated the greatest efficacy against acute and chronic experimental toxoplasmosis. Although genetic analyses in other organisms have highlighted the importance of the cytochrome bc1 complex Qi site for ELQ sensitivity, the mechanism of action of ELQs against T. gondii and the specific mechanism of ELQ-316 remain unknown. Here, we describe the selection and genetic characterization of T. gondii clones resistant to ELQ-316. A T. gondii strain selected under ELQ-316 drug pressure was found to possess a Thr222-Pro amino acid substitution that confers 49-fold resistance to ELQ-316 and 19-fold resistance to antimycin, a well-characterized Qi site inhibitor. These findings provide further evidence for ELQ Qi site inhibition in T. gondii and greater insight into the interactions of Qi site inhibitors with the apicomplexan cytochrome bc1 complex.

Original languageEnglish (US)
Article numbere01866
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

4-Quinolones
Qi
Cytochromes b
Quinolones
Toxoplasma
Electron Transport Complex III
Toxoplasmosis
antimycin
Babesiosis
Eye Diseases
Brain Diseases
Amino Acid Substitution
Malaria
Parasites
Clone Cells

Keywords

  • Apicomplexan parasites
  • Cytochrome b
  • Cytochrome bc
  • Drug targets
  • Experimental therapeutics
  • Mechanisms of action
  • Mitochondria
  • Parasitology
  • Preclinical drug studies
  • Toxoplasma gondii

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Genetic evidence for cytochrome b Qi site inhibition by 4(1H)-quinolone-3-diarylethers and antimycin in Toxoplasma gondii. / Alday, P. Holland; Bruzual, Igor; Nilsen, Aaron; Pou, Sovitj; Winter, Rolf; Mamoun, Choukri Ben; Riscoe, Michael; Doggett, Joseph.

In: Antimicrobial Agents and Chemotherapy, Vol. 61, No. 2, e01866, 01.02.2017.

Research output: Contribution to journalArticle

@article{f9a71d6f38b44ecc8d2e402d1236bdcc,
title = "Genetic evidence for cytochrome b Qi site inhibition by 4(1H)-quinolone-3-diarylethers and antimycin in Toxoplasma gondii",
abstract = "Toxoplasma gondii is an apicomplexan parasite that causes fatal and debilitating brain and eye disease. Endochinlike quinolones (ELQs) are preclinical compounds that are efficacious against apicomplexan-caused diseases, including toxoplasmosis, malaria, and babesiosis. Of the ELQs, ELQ-316 has demonstrated the greatest efficacy against acute and chronic experimental toxoplasmosis. Although genetic analyses in other organisms have highlighted the importance of the cytochrome bc1 complex Qi site for ELQ sensitivity, the mechanism of action of ELQs against T. gondii and the specific mechanism of ELQ-316 remain unknown. Here, we describe the selection and genetic characterization of T. gondii clones resistant to ELQ-316. A T. gondii strain selected under ELQ-316 drug pressure was found to possess a Thr222-Pro amino acid substitution that confers 49-fold resistance to ELQ-316 and 19-fold resistance to antimycin, a well-characterized Qi site inhibitor. These findings provide further evidence for ELQ Qi site inhibition in T. gondii and greater insight into the interactions of Qi site inhibitors with the apicomplexan cytochrome bc1 complex.",
keywords = "Apicomplexan parasites, Cytochrome b, Cytochrome bc, Drug targets, Experimental therapeutics, Mechanisms of action, Mitochondria, Parasitology, Preclinical drug studies, Toxoplasma gondii",
author = "Alday, {P. Holland} and Igor Bruzual and Aaron Nilsen and Sovitj Pou and Rolf Winter and Mamoun, {Choukri Ben} and Michael Riscoe and Joseph Doggett",
year = "2017",
month = "2",
day = "1",
doi = "10.1128/AAC.01866-16",
language = "English (US)",
volume = "61",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Genetic evidence for cytochrome b Qi site inhibition by 4(1H)-quinolone-3-diarylethers and antimycin in Toxoplasma gondii

AU - Alday, P. Holland

AU - Bruzual, Igor

AU - Nilsen, Aaron

AU - Pou, Sovitj

AU - Winter, Rolf

AU - Mamoun, Choukri Ben

AU - Riscoe, Michael

AU - Doggett, Joseph

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Toxoplasma gondii is an apicomplexan parasite that causes fatal and debilitating brain and eye disease. Endochinlike quinolones (ELQs) are preclinical compounds that are efficacious against apicomplexan-caused diseases, including toxoplasmosis, malaria, and babesiosis. Of the ELQs, ELQ-316 has demonstrated the greatest efficacy against acute and chronic experimental toxoplasmosis. Although genetic analyses in other organisms have highlighted the importance of the cytochrome bc1 complex Qi site for ELQ sensitivity, the mechanism of action of ELQs against T. gondii and the specific mechanism of ELQ-316 remain unknown. Here, we describe the selection and genetic characterization of T. gondii clones resistant to ELQ-316. A T. gondii strain selected under ELQ-316 drug pressure was found to possess a Thr222-Pro amino acid substitution that confers 49-fold resistance to ELQ-316 and 19-fold resistance to antimycin, a well-characterized Qi site inhibitor. These findings provide further evidence for ELQ Qi site inhibition in T. gondii and greater insight into the interactions of Qi site inhibitors with the apicomplexan cytochrome bc1 complex.

AB - Toxoplasma gondii is an apicomplexan parasite that causes fatal and debilitating brain and eye disease. Endochinlike quinolones (ELQs) are preclinical compounds that are efficacious against apicomplexan-caused diseases, including toxoplasmosis, malaria, and babesiosis. Of the ELQs, ELQ-316 has demonstrated the greatest efficacy against acute and chronic experimental toxoplasmosis. Although genetic analyses in other organisms have highlighted the importance of the cytochrome bc1 complex Qi site for ELQ sensitivity, the mechanism of action of ELQs against T. gondii and the specific mechanism of ELQ-316 remain unknown. Here, we describe the selection and genetic characterization of T. gondii clones resistant to ELQ-316. A T. gondii strain selected under ELQ-316 drug pressure was found to possess a Thr222-Pro amino acid substitution that confers 49-fold resistance to ELQ-316 and 19-fold resistance to antimycin, a well-characterized Qi site inhibitor. These findings provide further evidence for ELQ Qi site inhibition in T. gondii and greater insight into the interactions of Qi site inhibitors with the apicomplexan cytochrome bc1 complex.

KW - Apicomplexan parasites

KW - Cytochrome b

KW - Cytochrome bc

KW - Drug targets

KW - Experimental therapeutics

KW - Mechanisms of action

KW - Mitochondria

KW - Parasitology

KW - Preclinical drug studies

KW - Toxoplasma gondii

UR - http://www.scopus.com/inward/record.url?scp=85010934737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010934737&partnerID=8YFLogxK

U2 - 10.1128/AAC.01866-16

DO - 10.1128/AAC.01866-16

M3 - Article

C2 - 27919897

AN - SCOPUS:85010934737

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

M1 - e01866

ER -